Konar Center for Digestive and Liver Diseases, School of Medicine and Dentistry, University of Rochester, Rochester, New York 14642
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
5-Hydroxytryptamine
(serotonin, 5-HT) is a hormone and neurotransmitter regulating
gastrointestinal functions. 5-HT receptors are widely distributed in
gastrointestinal mucosa and the enteric nervous system. Duodenal
acidification stimulates not only the release of both 5-HT and secretin
but also pancreatic exocrine secretion. We investigated the effect of
5-HT receptor antagonists on the release of secretin and pancreatic
secretion of water and bicarbonate induced by duodenal acidification in
anesthetized rats. Both the 5-HT2 receptor antagonist
ketanserin and the 5-HT3 receptor antagonist ondansetron
at 1-100 µg/kg dose-dependently inhibited acid-induced
increases in plasma secretin concentration and pancreatic exocrine
secretion. Neither the 5-HT1 receptor antagonists pindolol
and 5-HTP-DP nor the 5-HT4 receptor antagonist SDZ-205,557
affected acid-evoked release of secretin or pancreatic secretion. None
of the 5-HT receptor antagonists affected basal pancreatic secretion or
plasma secretin concentration. Ketanserin or ondansetron at 10 µg/kg
or a combination of both suppressed the pancreatic secretion in
response to intravenous secretin at 2.5 and 5 pmol · kg1 · h
1 by
55-75%, but not at 10 pmol · kg
1 · h
1. Atropine
(50 µg/kg) significantly attenuated the inhibitory effect of
ketanserin on pancreatic secretion but not on the release of secretin.
These observations suggest that 5-HT2 and 5-HT3
receptors mediate duodenal acidification-induced release of secretin
and pancreatic secretion of fluid and bicarbonate. Also, regulation of
pancreatic exocrine secretion through 5-HT2 receptors may
involve a cholinergic pathway in the rat.
5-hydroxytryptamine; 5-hydroxytryptamine receptor; pancreatic exocrine secretion; atropine; rat
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
ALTHOUGH 5-HYDROXYTRYPTAMINE (5-HT) is widely distributed throughout the body, the largest store of 5-HT is found in the gastrointestinal tract. More than 90% of 5-HT is localized in the enterochromaffin (EC) cells of gastrointestinal mucosal epithelia and the enteric neurons. 5-HT is secreted from EC cells in response to a variety of luminal mechanical and chemical stimuli and activates neural circuits within the gastrointestinal wall. 5-HT is an important neurotransmitter and intercellular messenger to modulate gastrointestinal functions (14). 5-HT stimulates or inhibits gastrointestinal motility (8), alters gastric acid secretion (46), and enhances intestinal secretions (13, 56). Immunohistochemical study of gut mucosae (12) has demonstrated that EC cells together with other enteroendocrine cells have a morphological feature consistent with a paracrine action that may play a regulatory role in the release of gut hormones.
Through pharmacological studies and molecular cloning (1, 18, 42), at least seven families of 5-HT receptor subtypes, including 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7, have been discovered. Each subtype of 5-HT receptor is involved in various regulatory functions in different organs (18). Kirchgessner et al. (26, 28) have demonstrated the presence of 5-HT1A and 5-HT1P receptors in the pancreas. 5-HT immunoreactivity was also found in pancreatic ganglia, acinar nerves, and glucagon-immunoreactive islet cells, which are innervated by serotonergic enteropancreatic axons (23, 27, 29). Recently, Li and Owyang (33) reported that both 5-HT2 and 5-HT3 receptors mediate peptone-stimulated pancreatic protein secretion that is mediated by a luminal CCK-releasing peptide in rats.
Secretin is a major gut hormone located in S cells of the upper small intestinal mucosa. Secretin is released from the upper small intestine in response to duodenal acidification. It stimulates pancreatic exocrine secretion in various animal species and humans. The action and release of secretin in response to luminal stimulation are mediated by neural and hormonal mechanisms (7, 44). The results of immunohistochemical studies have indicated that secretin- and 5-HT-containing cells coexist in the intestinal mucosa (40). Duodenal acidification stimulates the release of not only secretin but also 5-HT from the intestinal mucosa (41), but little is known about the role of 5-HT in regulation of release and action of secretin and pancreatic exocrine secretion.
The aim of the present study was to test the hypothesis that certain 5-HT receptor subtypes are involved in duodenal acidification-elicited release of secretin and in the action of secretin on pancreatic exocrine secretion. Therefore, we determined the effect of antagonists of different 5-HT receptor subtypes on basal and acid-stimulated pancreatic exocrine secretion and the release of secretin in anesthetized rats. To gain further insight into the neural pathway involved with action of 5-HT receptors, atropine was administered in the rats treated with 5-HT receptor antagonists.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials. Synthetic porcine secretin was a kind gift of Dr. David Coy (Tulane University, New Orleans, LA). Pindolol (a 5-HT1 receptor antagonist), ketanserin (a 5-HT2 receptor antagonist), and SDZ-205,557 (a 5-HT4 receptor antagonist) were purchased from Research Biochemicals (Natick, MA). N-acetyl-5-hydroxytryptophyl-5-hydroxytryptophan amide (5-HTP-DP; a 5-HT1P receptor antagonist) was purchased from the Research Foundation for Mental Hygiene (New York, NY). Ondansetron (a 5-HT3 receptor antagonist) was purchased from Glaxo-Wellcome. Atropine was purchased from Gensie Pharmaceutical (Irvine, CA).
Animal preparation. Male Sprague-Dawley rats weighing 250-280 g were used in the experiments. The animals were housed under controlled temperature (23°C) and were fasted for 24 h with free access to tap water before surgery. Under anesthesia with 0.4 ml of 25% urethan/100 g body wt administered intraperitoneally, a midline abdominal incision was made. A polyethylene tube (ID 3.0 mm, OD 4.0 mm) was inserted in the proximal duodenum 5 mm distal to the pylorus via the stomach followed by ligation of the pylorus for intraduodenal infusion of 0.03 N HCl or 0.15 M NaCl. A pancreatic duct cannula was made by inserting a PE-10 tube (ID 0.28 mm, OD 0.61 mm) at the junction between the pancreatic duct and the duodenal wall for collection of pancreatic juice. Another PE-10 tube was cannulated in the bile duct proximal to the pancreatic duct for diversion of bile to the exterior. The jugular vein was catheterized using a PE-50 tube (ID 0.58 mm, OD 0.96 mm). The tube was kept patent by infusing 0.15 M NaCl solution at a flow rate of 1 ml/h for injection of 5-HT receptor antagonists.
Experimental design. Experiments were started in each group of five rats 30 min after surgery. To study the effect of 5-HT receptors on basal pancreatic secretion, 0.15 M NaCl was infused intraduodenally at 4.5 ml/h for 90 min after 75 min of measurement of basal pancreatic secretion. At 60 min, vehicle or a 5-HT receptor antagonist [pindolol (1 mg/kg), 5-HTP-DP (1 mg/kg), ketanserin (0.1 mg/kg), ondansetron (0.1 mg/kg), or SDZ-205,557 (1 mg/kg)] was administered intravenously 15 min before 0.15 M NaCl was infused. Pancreatic secretion of fluid and bicarbonate during the 90-min period after NaCl infusion was determined. To study the role of 5-HT receptors in endogenous secretin-stimulated pancreatic secretion by duodenal acidification, the receptor antagonist was injected intravenously 15 min before 0.03 N HCl was infused intraduodenally at 4.5 ml/h for 90 min. However, pindolol (0.1 mg/kg), 5-HTP-DP (0.5 mg/kg), SDZ-205,557 (1 mg/kg), or ketanserin or ondansetron (1, 5, 10, 50, and 100 µg/kg) was infused in this study. The doses of these antagonists were either used in previous studies (10, 33) or determined as effective in the present study.
To investigate the effect of 5-HT receptors on exogenous secretin-induced pancreatic secretion, synthetic porcine secretin in three stepwise increasing doses (2.5, 5, and 10 pmol · kgMeasurement.
Pancreatic juice was collected continuously in a glass micropipette
(Drummond Scientific, San Francisco, CA) in 30-min samples. The volume
of pancreatic fluid was measured by calculating the length of
pancreatic juice in the micropipette with a capacity of 3.85 µl/cm
tube length. After measurement of the length of the juice in the
micropipette, the pancreatic juice was immediately blown into an
ice-chilled microcentrifuge tube with a rubber bulb and was capped. Ten
microliters of the juice were taken for determination of bicarbonate
concentration using a model 965 Carbon Dioxide Analyzer (Ciba-Corning
Diagnostics, Halstead, UK). The result was expressed as
microequivalents of bicarbonate secreted per 30 min. At the end of each
experiment, blood samples were drawn immediately from the aorta and
collected into ice-chilled heparinized glass tubes. Plasma was obtained
by centrifugation and was stored at 70°C. Plasma secretin level was
measured by a specific RIA method as described previously (6,
45).
Statistical analysis. All data were calculated and expressed graphically as means ± SE. The volume and bicarbonate outputs of pancreatic fluid from the last 60-min samples during each treatment were compared with those from the 60-min samples in the basal period and were expressed as a percentage increase over the basal value. The effect of a 5-HT antagonist was then compared with that of the control during the basal state (0.15 M NaCl infused intraduodenally) or duodenal acidification. Statistical analysis of data was accomplished by one-way ANOVA. Tukey's post hoc test was used for multiple comparisons. A value of P < 0.05 was considered statistically significant.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Effects of 5-HT receptor antagonists on basal pancreatic secretion.
During the basal period, pancreatic exocrine secretion was stable with
secretion of fluid and bicarbonate at 17.4 ± 3.2 µl/30 min and
0.54 ± 0.15 µeq/30 min, respectively. Neither 0.15 M NaCl infused intraduodenally nor any of the 5-HT receptor antagonists tested
significantly influenced basal pancreatic secretion, although ketanserin at 100 µg/kg or SDZ-205,557 at 1 mg/kg slightly reduced pancreatic secretion (Table 1). Basal
plasma secretin concentration was 1.8 ± 0.5 pM and was not
influenced by either 0.15 M NaCl or any of the 5-HT receptor
antagonists tested (Table 1).
|
Effect of 5-HT receptor antagonists on acid-stimulated pancreatic
secretion and release of secretin.
Duodenal acidification with 0.03 N HCl significantly increased
pancreatic secretion of fluid and bicarbonate by 78.2 ± 6.4 and
146.0 ± 26.4%, respectively, over the basal secretion and was
significantly higher than that observed in the control rats infused
intraduodenally with 0.15 M NaCl (Table 1). Concomitantly, plasma
secretin level increased from 1.7 ± 0.4 to 5.9 ± 0.8 pM. As
shown in Table 2, pindolol, 5-HTP-DP, or
SDZ-205,557 did not affect significantly the acid-stimulated increases
in pancreatic secretion and plasma secretin concentration. In contrast,
ketanserin and ondansetron dose-dependently inhibited pancreatic
secretions of fluid and bicarbonate as well as the increase of plasma
secretin concentration in response to duodenal acidification.
Ketanserin produced maximal inhibitions of 85% in fluid (decreased to
11.4 ± 7.6% over basal secretion) and 82% in bicarbonate
(decreased to 27.0 ± 10.1% over basal) secretion and a 56%
decrease in plasma secretin concentration (decreased to 2.6 ± 0.2 pM; Fig. 1). Similarly, ondansetron
produced maximal inhibitions of 82% in fluid (to 14.0 ± 7.6%
over basal) and 82% in bicarbonate (to 26.0 ± 6.3% over basal)
secretion and a 67.8% decrease in plasma secretin concentration (to
1.9 ± 0.2 pM; Fig. 2). Both
ketanserin and ondansetron produced maximal inhibition at a dose of 50 µg/kg.
|
|
|
Effect of ketanserin and ondansetron on pancreatic secretion in
response to exogenous secretin.
Secretin at 2.5, 5, and 10 pmol · kg1 · h
1 iv
dose-dependently increased pancreatic fluid and bicarbonate secretion
(Fig. 3). The stimulatory effect observed
with 5 pmol · kg
1 · h
1 with
an increase of 70.4 ± 11.9% and 123.9 ± 19.4% over basal secretion in volume and bicarbonate output, respectively, was similar
to that observed with intraduodenal infusion of 0.03 N HCl. The effect
of 10 pmol · kg
1 · h
1 of
secretin, on the other hand, with a 121.2 ± 9.8% increase in
volume and 201.8 ± 25.6% in bicarbonate output over basal
secretion was nearly two times as much as that stimulated by 0.03 N
HCl. Both ketanserin and ondansetron at 10 µg/kg significantly
suppressed pancreatic secretion in response to intravenous secretin at
2.5 and 5 pmol · kg
1 · h
1
but not at 10 pmol · kg
1 · h
1 (Fig. 3).
For instance, ketanserin decreased volume and bicarbonate secretion
stimulated by secretin at 5 pmol · kg
1 · h
1 to
36.4 ± 10.1% and 67.7 ± 13.0% over basal secretion,
respectively, while ondansetron decreased the values to 45.2 ± 6.4% and 76.5 ± 8.5%, respectively. On the other hand,
pancreatic secretion in response to secretin at 10 pmol · kg
1 · h
1 was not
significantly affected by ketanserin (volume secretion: 105 ± 28%; bicarbonate: 194 ± 51% over basal) or by ondansetron (volume: 114 ± 29%; bicarbonate: 160 ± 26% over basal).
When ketanserin and ondansetron were administered together, pancreatic
secretion of volume and bicarbonate in response to secretin at 5 pmol · kg
1 · h
1 was
decreased to 32.6 ± 8.6% and 47.9 ± 5.9% over basal,
respectively. However, the decrease was not significantly different
from that produced by ketanserin or ondansetron alone. In contrast,
pancreatic secretion in response to secretin at 10 pmol · kg
1 · h
1 in the
presence of both 5-HT receptor antagonists (122 ± 28 and 203 ± 16% over basal, respectively) was not significantly different from
that observed with secretin alone. Similarly, the 5-HT1
receptor antagonists pindolol and 5-HTP-DP did not affect pancreatic
secretion stimulated by secretin given intravenously at all doses (data not shown). The 5-HT4 receptor antagonist SDZ-205,557 also
did not affect pancreatic secretion stimulated by all three doses of
secretin. For instance, secretin at 5 pmol · kg
1 · h
1 in the
presence of SDZ-205,557 (1 mg/kg) produced an increase of fluid volume
by 70.4 ± 4.2% and bicarbonate output by 129.8 ± 11.1%
over basal secretion.
|
Effect of atropine on release of secretin and pancreatic secretion
in response to ketanserin and ondansetron.
Atropine at 50 µg/kg followed by 25 µg · kg1 · h
1 iv did not
influence the increase in plasma secretin level in response to duodenal
acidification. Atropine also did not affect inhibition of acid-evoked
secretin release by intravenous administration of ketanserin or
ondansetron at 10 µg/kg (Fig. 4,
bottom). However, atropine at the same dose significantly
reversed, albeit partially, the inhibition by ketanserin but not by
ondansetron of pancreatic exocrine secretion during duodenal
acidification (Fig. 4, top and
middle). Similarly, atropine also partially reversed the
inhibition by ketanserin of secretin (5 pmol · kg
1 · h
1)-stimulated
pancreatic fluid secretion by 52% (from 36.4 ± 10.4% to
54.1 ± 6.3% over basal, P < 0.05) and
bicarbonate output by 64.5% (from 67.7 ± 13.0% to 104.0 ± 14.7%, P < 0.05; Fig. 5). Again, atropine
did not influence ondansetron-inhibited pancreatic secretion in
response to secretin (Fig. 5). In control experiments, neither
the release of secretin nor pancreatic fluid and bicarbonate secretion
in response to acid was significantly influenced by atropine (data not
shown).
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The results of the present study have demonstrated for the first
time that both 5-HT2 and 5-HT3 receptors play
significant roles in the mechanisms of the release and action of
secretin on pancreatic exocrine secretion in response to duodenal
acidification. We have observed that both the 5-HT2
receptor antagonist ketanserin and the 5-HT3 receptor
antagonist ondansetron dose-dependently inhibit the duodenal
acidification-elicited increase in pancreatic exocrine secretion of
fluid and bicarbonate as well as elevation of plasma secretin
concentration. These results suggest that both of these 5-HT receptor
subtypes are involved in the release of secretin stimulated by duodenal
acidification. We have also observed that these two antagonists
inhibited pancreatic exocrine secretion in response to exogenous
secretin at a dose up to 5 pmol · kg1 · h
1 but
not at 10 pmol · kg
1 · h
1.
It has been shown previously that exogenous secretin at 5 pmol · kg
1 · h
1 produces
plasma secretin levels comparable to postprandial plasma levels
of secretin and thus is regarded as a physiological dose (6,
30). For the same reason, the dose of secretin higher than 5 pmol · kg
1 · h
1, such as 10 pmol · kg
1 · h
1 or higher,
which raises plasma secretin levels much higher than that found after a
meal, is regarded as a pharmacological dose. Therefore, it appears that
both 5-HT2 and 5-HT3 receptors mediate only the
physiological but not pharmacological action of secretin on the
exocrine pancreas. However, the involvement of the 5-HT receptor
appears to be receptor subtype selective, as the antagonists of
5-HT1 and 5-HT4 receptors had no effect on
acid-evoked release of secretin or the action of exogenous secretin. It
should be noted that the lack of an effect by the 5-HT4
receptor antagonist SDZ-205,557 suggested that the inhibitory effects
of ondansetron mentioned above were not due to its weak interaction at
the 5-HT4 receptor. These observations appear to parallel
with the observation by Li and Owyang (33) that both
5-HT2 and 5-HT3 receptors are involved in
peptone meal-elicited release of CCK-releasing peptide and CCK in the
rat. The receptor subtype selectivity appears to vary in 5-HT-mediated
secretion from rat small intestinal mucosa. The release of 5-HT from
the EC cells is regulated by 5-HT3 and 5-HT4
receptors (37). Cholera toxin-induced mucin secretion was
in part mediated only by 5-HT4 receptors in a
capsaicin-sensitive pathway (38). On the other hand,
5-HT-stimulated fluid and electrolyte secretion involve
5-HT2, 5-HT3, and 5-HT4 receptors
(36).
The mechanisms or pathways of 5-HT2 and 5-HT3 receptors that mediate acid-elicited release of secretin are not clear at present. Duodenal acidification is a potent luminal stimulation to evoke the release of both secretin (6) and 5-HT (41). It has been shown that the release of secretin by duodenal acidification is mediated through the release of a secretin-releasing peptide (SRP; see Ref. 31). In addition, the release of SRP and secretin by duodenal acidification is mediated through a vagal sensory afferent pathway (30). 5-HT is known to be present both in EC cells in the intestinal mucosa (11) and in enteric neurons (9). It is possible that 5-HT is released from EC cells as a paracrine messenger or perhaps, in part, from intrinsic neurons as a neurotransmitter in the gastrointestinal tract (14, 51). Thus, similar to its effects on fluid and electrolyte secretion (36), 5-HT as a paracrine messenger could act directly on 5-HT2 and 5-HT3 receptors in the membrane of cells containing SRP or S cells to trigger the release of secretin. So far, it remains unknown whether 5-HT receptors are present in these cells. Electrophysiological studies have identified the existence of 5-HT3 receptors in pre- and postganglionic autonomic neurons and in neurons of the sensory and enteric nervous system (18, 21, 51). In the rat, 5-HT3 receptor is detected in both submucosal and myenteric ganglia (19). Thus it is possible that 5-HT acting on the 5-HT3 receptor in sensory afferent neurons and nerve endings in submucous and myenteric plexuses of the enteric nervous system may trigger the release of SRP and/or secretin. The presence of 5-HT2 receptors in the enteric nervous system is not well documented. However, it has been reported that the 5-HT2 receptor mediates jejunal mesenteric afferent discharge in the rat (17). It is possible that the 5-HT2 receptor mediates acid-evoked secretin release through a similar mechanism.
The mechanism or mechanisms through which 5-HT2 and
5-HT3 receptors mediate the action of secretin on
pancreatic exocrine secretion are also unclear at present. However,
these receptors appear to play significant roles only when secretin is
endogenously released or given in a physiological dose. Thus the
antagonist of both 5-HT2 and 5-HT3 receptors
failed to inhibit pancreatic exocrine secretion when it was stimulated
by a pharmacological dose of secretin such as 10 pmol · kg1 · h
1. This
observation indicates that secretin at a pharmacological dose is able
to act on the exocrine pancreas without mediation by the two 5-HT
receptors. In a previous study (32) we observed that
stimulation of pancreatic exocrine secretion by secretin in
physiological doses was mediated through a capsaicin-sensitive ascending vagal sensory pathway. On the other hand, secretin in a
pharmacological dose appeared to override the mediation via the
ascending sensory pathway of the vagi. Hillsley and Grundy (16) reported that duodenal luminal perfusion with 150 mM
HCl significantly increased mesenteric afferent nerve discharge that was not suppressed by a 5-HT3 receptor antagonist. Such a
concentrated HCl solution is known to elevate plasma secretin above
physiological concentrations (6, 30). Thus the electrical
activity in the afferent nerve elicited by concentrated acid appeared
to be a pharmacological effect and would not be affected by a
5-HT3 receptor antagonist in a similar fashion. It has been
reported (51) that excitation of vagal afferent nerves by
5-HT in anesthetized rats is mediated by both 5-HT2 and
5-HT3 but not by 5-HT1 or 5-HT4 receptors. 5-HT was found to excite a large portion of afferent neurons
in the dorsal motor nucleus of the vagus projecting to the duodenum and
stomach in a ketanserin-sensitive manner (4). Both
5-HT2 and 5-HT3 receptor subtypes are also
present in the dorsal vagal complex (50, 54) that supplies
efferent fibers to the gut. Kirchgessner and Gershon (22)
have demonstrated in the rat that vagal efferent fibers terminate
predominantly in the myenteric plexus of the stomach and duodenum. The
myenteric neurons receiving vagal efferent innervation are either 5-HT- or vasoactive intestinal peptide-containing neurons. These authors also
demonstrated that the pancreas receives extrinsic innervation mainly
from the myenteric plexus of the stomach and duodenum
(23). Some of these neurons contain 5-HT and terminate
mainly in pancreatic ganglia, some of them in the vicinity of acini,
ducts, vessels, and islets. Thus, although both 5-HT2 and
5-HT3 receptors play significant roles in the ascending
vagal sensory pathway-mediated pancreatic exocrine secretion, their
sites of participation are not clear at present. It is possible that
luminal acid also stimulates the release of 5-HT from both enteric and
pancreatic serotonergic neurons, which in turn may potentiate the
effect of secretin on ductular water and bicarbonate secretion by
acting on 5-HT3 receptors. This mode of action by the 5-HT
receptors is very similar to that reported by other investigators. Thus
activation of 5-HT3 receptor by a selective
5-HT3 agonist, 2-methyl-5-HT, stimulated basal amylase
secretion (24), whereas a 5-HT3 antagonist,
ICS-205,930, inhibited peptone-induced pancreatic protein secretion
(33). So far, 5-HT2 receptor has not been
found in the pancreas, although it is widely distributed in the central
nervous system (CNS) and peripheral tissues (3,
18). It is possible that a 5-HT2 receptor in
sensory nerve fibers that connect to the vagal afferent pathway mediates the action of secretin. Alternatively, 5-HT2 and
5-HT3 receptors may be localized in different subset of
vagal afferent nerves to mediate the action of secretin. This
proposition of separate localization of 5-HT2 and
5-HT3 receptors appears to help explain the different
sensitivity toward atropine between ketanserin- and ondansetron-induced
inhibitions of secretin-stimulated pancreatic exocrine secretion.
Moreover, because secretin-stimulated pancreatic exocrine secretion in
the rat is not sensitive to atropine (32, 30), it is very
likely that 5-HT2 receptor is involved in suppression of an
inhibitory neural pathway that attenuates the pathway stimulated by
secretin. Thus action of 5-HT on the 5-HT2 receptor may
activate a cholinergic receptor-dependent pathway that would suppress a
yet unidentified inhibitory neural pathway, thereby permitting
activation of the vagal afferent pathway by secretin. On the other
hand, antagonism with ketanserin at the 5-HT2 receptor
would remove the suppression, in an atropine-sensitive fashion, of the
inhibitory pathway that in turn inhibits the action of secretin. It
should be noted that, although this hypothetical inhibitory neural
pathway appears to provide a logical explanation of reversal by
atropine of ketanserin-produced inhibition of secretin-stimulated pancreatic exocrine secretion, its existence remains to be elucidated. In addition, we cannot totally rule out that 5-HT2 receptor
exists in the rat pancreas. These questions may be subjects of our
future study.
It should be noted that the present study was carried out in anesthetized rats that have been shown to have plasma somatostatin concentration elevated to inhibit basal gastric acid secretion (47, 53). Varga et al. (47) have shown that the elevated somatostatin concentration in the circulation has no effect on basal pancreatic exocrine secretion. On the other hand, these authors have shown that CCK-stimulated protein secretion in anesthetized rats is enhanced by immunoneutralization with a specific anti-somatostatin monoclonal antibody. This observation indicated that endogenous somatostatin participates in modulation of CCK- stimulated exocrine secretion. Lucey et al. (35) have shown that duodenal acidification elevated plasma somatostatin concentration in humans. Thus it is potentially possible that endogenous somatostatin is involved in 5-HT2 and 5-HT3 receptor-mediated pancreatic exocrine secretion.
Singer et al. (43) have proposed the existence of an enteropancreatic reflex mechanism to regulate pancreatic enzyme secretion in the dog. Kirchgessner and coworkers have provided the anatomic (23, 25) and functional (23) evidence of such an enteropancreatic neural pathway in both the guinea pig and rat to participate in regulation of pancreatic enzyme secretion. The enteropancreatic reflex mechanism appears to involve both 5-HT1A and 5-HT1P receptor subtypes (23, 27). In addition, these receptors appeared to involve an inhibitory pathway in the rat (24). In the present study, however, we found that neither pindolol nor 5-HTP-DP influenced basal or acid-induced pancreatic secretion of fluid and bicarbonate. It should be noted that, in the guinea pig, different mucosal stimulants have been shown to activate different subsets of submucosal neurons (28). Thus a similar enteropancreatic reflex mechanism may not be operating in acid- and secretin-stimulated ductal secretion of the rat pancreas. Alternatively, a similar reflex mechanism may exist without involving the 5-HT1 receptors. Nevertheless, whether 5-HT2 and 5-HT3 receptors are involved in the enteropancreatic reflex mechanism of pancreatic duct secretion remains unknown and requires further study.
The 5-HT4 receptor has been identified in the CNS and in a variety of tissues (3), including the vagus nerve (2). The presence of the 5-HT4 receptor in guinea pig enteric neurons (38, 48) and its function therein (20) have been documented. In the rat, the 5-HT4 receptor has been shown to mediate intestinal secretion (15, 36, 37) and motility (34, 52). In the present study, we were unable to observe that a 5-HT4 receptor-selective antagonist, SDZ 205,557 (5), influenced either basal or acid-stimulated release of secretin and exocrine pancreatic secretion of fluid and bicarbonate. This observation suggests that the 5-HT4 receptor may not participate in mediation of these functions. However, we cannot rule out that the absence of involvement by the 5-HT4 receptor in acid-induced secretin release and pancreatic exocrine secretion may be attributed to a species difference. It is probably worthwhile to test the role of 5-HT4 receptor in regulation of pancreatic exocrine secretion and the release of secretin in other species.
In summary, our results provide evidence for physiological roles of 5-HT2 and 5-HT3 receptors in the mechanisms of the release of secretin and pancreatic secretion of fluid and bicarbonate in response to duodenal acidification. Our data suggest that luminal acid in the duodenum may trigger EC cells to release 5-HT locally. 5-HT then activates 5-HT2 and 5-HT3 receptors in enteric submucosal and myenteric plexuses, which provide a neuronal pathway for the release of secretin to stimulate pancreatic exocrine secretion. Furthermore, the mechanism of pancreatic secretion of fluid and bicarbonate stimulated by exogenous secretin in a physiological dose or endogenous secretin probably involves 5-HT2 and 5-HT3 receptors in the vagal sensory afferent pathway.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Laura Braggins, David Wagner, and Frank Roth for technical assistance and figure preparation.
![]() |
FOOTNOTES |
---|
This study was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-25962.
Address for reprint requests and other correspondence: W. Y. Chey, Rochester Institute for Digestive Diseases and Sciences, 222 Alexander St., Suite 3100, Rochester, NY 14607 (E-mail: w.y.chey{at}inetmail.att.net).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 9 March 2000; accepted in final form 20 October 2000.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Bard, JA,
Zgombick J,
Adahm N,
Vaysse P,
Branchek TA,
and
Weinshank RL.
Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase.
J Biol Chem
268:
23422-23426,
1993
2.
Bley, KR,
Eglen RM,
and
Wong EH.
Characterization of 5-hydroxytryptamine-induced depolarization in rat isolated vagus nerve.
Eur J Pharmacol
260:
139-147,
1994[ISI][Medline].
3.
Bradley, PB,
Engel G,
Feniuk W,
Fozard JR,
Humphrey PPA,
Middlemiss DN,
Mylecharane EJ,
Richardson BP,
and
Saxena PR.
Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine.
Neuropharmacology
25:
563-576,
1986[ISI][Medline].
4.
Browning, KN,
and
Travagli RA.
Characterization of the in vitro effects of 5-hydroxytryptamine (5-HT) on identified neurons of the rat dorsal motor nucleus of the vagus (DMV).
Br J Pharmacol
128:
1307-1315,
1999
5.
Buchheit, K-H,
Gamse R,
and
Pfannkuche H-J.
SDZ 205-557, a selective, surmountable antagonist for 5-HT4 receptors in the isolated guinea pig ileum.
Naunyn Schmiedebergs Arch Pharmacol
345:
387-393,
1992[ISI][Medline].
6.
Chang, T-M,
and
Chey WY.
Radioimmunoassay of secretin: a critical review.
Dig Dis Sci
25:
529-552,
1980[ISI][Medline].
7.
Chey, WY.
Hormonal control of pancreatic exocrine secretion.
In: The Pancreas: Biology, Pathobiology, and Disease, , edited by Go VLW,
DiMagno EP,
Gardner JD,
Lebenthal E,
Reber HA,
and Scheele G.. New York: Raven, 1993, p. 403-424.
8.
Cook, HJ.
Neurobiology of the intestinal mucosa.
Gastroenterology
90:
1057-1081,
1986[ISI][Medline].
9.
Costa, M,
Furness JB,
Cuello AC,
Verhofstad AAJ,
Steinbusch HWJ,
and
Elde RP.
Neurons with 5-hydroxytryptamine-like immunoreactivity in the enteric nervous system: their visualization and reactions to drug treatment.
Neuroscience
7:
351-363,
1982[ISI][Medline].
10.
Croci, T,
Basilisco G,
Bassani A,
and
Manara L.
Manometric patterns of rat colonic motor activity and defecation. Effect of selective 5-HT1A agonist 8-OH-DPAT.
Dig Dis Sci
39:
1968-1973,
1994[ISI][Medline].
11.
Erspamer, V
Occurrence of indolealkylamines in nature.
In: Handbook of Experimental Pharmacology 5-Hydroxytryptamine and Related Indolealkylamines, edited by Erspamer V. New York: Springer-Verlag, 1996, vol. 19, p. 132-181.
12.
Fujita, T,
Kobayashi S,
Muraki S,
Sato K,
and
Shimoji K.
Gut endocrine cells as chemoreceptors.
In: Gut Peptides: Secretion, Function and Clinical Aspects, edited by Miyoshi A.. Tokyo, Japan: Kodansha/Elsevier, 1979, p. 47-52.
13.
Gershon, MD.
The enteric nervous system.
Annu Rev Neurosci
4:
227-272,
1981[ISI][Medline].
14.
Gershon, MD,
Drakontides AB,
and
Ross LL.
Serotonin: synthesis and release from the myenteric plexus of the mouse intestine.
Science
149:
197-199,
1965[ISI].
15.
Hansen, MB,
and
Jaffe BM.
5-HT receptor subtypes involved in luminal serotonin-induced secretion in rat intestine in vivo.
J Surg Res
56:
277-287,
1994[ISI][Medline].
16.
Hillsley, K,
and
Grundy D.
Sensitivity to 5-hydroxytryptamine in different afferent subpopulations within mesenteric nerves supplying the rat jejunum.
J Physiol (Lond)
509:
717-727,
1998
17.
Hillsley, K,
Kirkup AJ,
and
Grundy D.
Direct and indirect action of 5-hydroxytryptamine on the discharge of mesenteric afferent fibers innervating the rat jejunum.
J Physiol (Lond)
506:
551-561,
1998
18.
Hoyer, D,
Clarke DE,
Fozard JR,
Hartig PR,
Martin GR,
Myecharane EJ,
Saxena P,
and
Humphe PPA
International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin).
Pharmacol Rev
46:
127-203,
1994.
19.
Johnson, DS,
and
Heinemann SF.
Detection of 5-HT3R-A, a 5-HT3 receptor subunit, in submucosal and myenteric ganglia of rat small intestine using in situ hybridization.
Neurosci Lett
184:
67-70,
1995[ISI][Medline].
20.
Kilbinger, H,
and
Wolf D.
Effects of 5-HT4 receptor stimulation on basal and electrically evoked release of acetylcholine from guinea-pig myenteric plexus.
Naunyn Schmiedebergs Arch Pharmacol
345:
270-275,
1992[ISI][Medline].
21.
Kilpatrick, GJ,
Jones BJ,
and
Tyers MB.
Binding of the 5-HT3 ligand 3H GR65630 to rat area postrema, vagus nerve and the brains of several species.
Eur J Pharmacol
159:
157-164,
1989[ISI][Medline].
22.
Kirchgessner, AL,
and
Gershon MD.
Identification of vagal efferent fibers and putative target neurons in the enteric nervous system of the rat.
J Comp Neurol
285:
38-53,
1989[ISI][Medline].
23.
Kirchgessner, AL,
and
Gershon MD.
Innervation of the pancreas by neurons in the gut.
J Neurosci
10:
1626-1642,
1990[Abstract].
24.
Kirchgessner, AL,
and
Gershon MD.
Presynaptic inhibition by serotonin of nerve-mediated secretion of pancreatic amylase.
Am J Physiol Gastrointest Liver Physiol
268:
G339-G345,
1995
25.
Kirchgessner, AL,
Liu M-T,
and
Gershon MD.
In situ identification and visualization of neurons that mediate enteric and enteropancreatic reflexes.
J Comp Neurol
371:
270-286,
1996[ISI][Medline].
26.
Kirchgessner, AL,
Liu M-T,
Howard MJ,
and
Gershon MD.
Detection of the 5-HT1A receptor and 5-HT1A receptor mRNA in the rat bowel and pancreas: comparison with 5-HT1P receptors.
J Comp Neurol
327:
233-250,
1993[ISI][Medline].
27.
Kirchgessner, AL,
Liu M-T,
Raymond JR,
and
Gershon MD.
Identification of cells that express 5-hydroxytryptamine1A receptors in the nervous systems of the bowel and pancreas.
J Comp Neurol
364:
439-455,
1996[ISI][Medline].
28.
Kirchgessner, AL,
Tamir H,
and
Gershon MD.
Identification and stimulation by serotonin of intrinsic sensory neurons of the submucosal plexus of the guinea pig gut: activity-induced expression of Fos immunoreactivity.
J Neurosci
12:
235-248,
1992[Abstract].
29.
Koevary, SB,
McEvoy RC,
and
Azmitia EC.
Specific uptake of tritiated serotonin in the adult rat pancreas: evidence for the presence of serotonergic fibers.
Am J Anat
159:
361-368,
1980[ISI][Medline].
30.
Li, P,
Chang T-M,
and
Chey WY.
Neuronal regulation of the release and action of secretin-releasing peptide and secretin.
Am J Physiol Gastrointest Liver Physiol
269:
G305-G312,
1995
31.
Li, P,
Lee KY,
Chang T-M,
and
Chey WY.
Mechanism of acid-induced release of secretin in rats: presence of a secretin-releasing peptide.
J Clin Invest
86:
1474-1479,
1990[ISI][Medline].
32.
Li, P,
Lee KY,
Chang T-M,
and
Chey WY.
Hormonal mechanism of sodium oleate-stimulated pancreatic secretion in rats.
Am J Physiol Gastrointest Liver Physiol
259:
G960-G965,
1990
33.
Li, Y,
and
Owyang C.
Peptone stimulates CCK-releasing peptide secretion by activating intestinal submucosal cholinergic neurons.
J Clin Invest
97:
1463-1470,
1996
34.
Lordal, M,
and
Hellstrom PM.
Serotonin stimulates migrating myoelectric complex via 5-HT3-receptors dependent on cholinergic pathways in rat small intestine.
Neurogastroenterol Motil
11:
1-10,
1999[ISI][Medline].
35.
Lucey, MR,
Mass JAH,
Fairclough PD,
O'Hare M,
Kwasowski P,
Penman E,
Wegg J,
and
Rees LH.
Does gastric acid release plasma somatostatin in man?
Gut
25:
1217-1220,
1984[Abstract].
36.
McLean, PG,
and
Coupar IM.
Investigation into the effect of 5-hydroxytryptamine on fluid transport in the rat small intestine.
Gen Pharmacol
30:
227-231,
1998[Medline].
37.
Minami, M,
Tamakai H,
Ogawa T,
Endo T,
Hamaue N,
Hirafuji M,
Yoshioka M,
and
Blower PR.
Chemical modulation of 5-HT3 and 5-HT4 receptors affects the release of 5-hydroxytryptamine from the ferret and rat intestine.
Res Commun Mol Pathol Pharmacol
89:
131-142,
1995[ISI][Medline].
38.
Moore, BA,
Sharkey KA,
and
Mantle M.
Role of 5-HT in cholera toxin-induced mucin secretion in the rat small intestine.
Am J Physiol Gastrointest Liver Physiol
270:
G1001-G1009,
1996
39.
Pan, H,
and
Galligan JJ.
5-HT1A and 5-HT4 receptors mediate inhibition and facilitation of fast synaptic transmission in enteric neurons.
Am J Physiol Gastrointest Liver Physiol
266:
G230-G238,
1994
40.
Polak, JM.
Endocrine cells of the gut.
In: Handbook of Physiology. The Gastrointestestinal System. Neural and Endocrine Biology. Bethesda, MD: Am Physiol Soc, 1989, sect. 6, vol. II, chapt. 4, p. 79-96.
41.
Resnick, RH,
and
Gray SJ.
Serotonin release by hydrochloric acid. I. In vivo and in vitro demonstration.
J Lab Clin Med
59:
462-468,
1962[ISI].
42.
Schmidt, AW,
and
Peroutka SJ.
5-Hydroxytryptamine receptor "families."
FASEB J
3:
2242-2249,
1989
43.
Singer, MV,
Solomon TE,
Wood J,
and
Grossman MI.
Latency of pancreatic enzyme response to intraduodenal stimulants.
Am J Physiol Gastrointest Liver Physiol
238:
G23-G29,
1980
44.
Solomon, TE.
Control of exocrine pancreatic secretion.
In: Physiology of the Gastrointestinal Tract, edited by Johnson LR.. New York: Raven, 1994, p. 1499-1529.
45.
Tai, HH,
and
Chey WY.
Rapid extraction of secretin from plasma by XAD-2 resin and its application in the radioimmunoassay of secretin.
Anal Biochem
87:
376-385,
1978[ISI][Medline].
46.
Varanasi, S,
Chi J,
and
Stephens RL, Jr.
5-CT or DOI augments TRH analog induced gastric acid secretion at the dorsal vagal complex.
Am J Physiol Regulatory Integrative Comp Physiol
273:
R1607-R1611,
1997
47.
Varga, G,
Kisfalvi I, Jr,
Kordas K,
Wong H,
Walsh JH,
and
Solomon TE.
Effect of somatostatin immunoneutralization on gastric acid and pancreatic enzyme secretion in anesthetized rats.
J Physiol (Lond)
91:
223-227,
1997.
48.
Wade, PR,
Tamir H,
Kirchgessner AL,
and
Gershon MD.
Analysis of the role of 5-HT in the enteric nervous system using anti-idiotypic antibodies to 5-HT receptors.
Am J Physiol Gastrointest Liver Physiol
266:
G403-G416,
1994
49.
Wallis, DL,
and
Elliott P.
The electrophysiology of 5-HT.
In: Serotonin: Molecular Biology, Receptors and Functional Effect, edited by Fozard JR,
and Saxena PR.. Basel, Switzerland: Birkhauser Verlag, 1991, p. 203-219.
50.
Wang, Y,
Ramage AG,
and
Jordan D.
Mediation by 5-HT3 receptor of an excitatory effect of 5-HT on dorsal vagal preganglionic neurons in anaesthetized rats: an ionophoretic study.
Br J Pharmacol
118:
1697-1704,
1996[Abstract].
51.
Wood, JD.
Messenger function of serotonin in the enteric nervous system.
In: Serotonin: From Cell Biology to Pharmacology and Therapeutics, edited by Paolett R,
Vanhoutte PM,
Burnello N,
and Meggi FM.. London: Kluwer Scientific, 1990, p. 241-249.
52.
Yamamoto, I,
Kuwahara A,
Fujimura M,
Kadowqki M,
and
Fujimiya M.
Involvement of 5-HT3 and 5-HT4 receptors in the motor activity of isolated vascularly perfused rat duodenum.
Neurogastroenterol Motil
11:
457-465,
1999[ISI][Medline].
53.
Yang, H,
Wong H,
Wu V,
Walsh JH,
and
Tache Y.
Somatostatin monoclonal antibody immunoneutralization increases gastrin and gastric acid secretion in urethane-anesthetized rats.
Gastroenterology
99:
659-665,
1990[ISI][Medline].
54.
Yoneda, M,
and
Tache Y.
Serotonin enhances gastric acid response to TRH analogue in dorsal vagal complex through 5-HT2 receptors in rats.
Am J Physiol Regulatory Integrative Comp Physiol
269:
R1-R6,
1995
55.
Yoshioka, M,
Ikeda T,
Abe M,
Togashi H,
Minami M,
and
Saito H.
Pharmacological characterization of 5-hydroxytryptamine-induced excitation of afferent cervical vagus nerve in anaesthetized rats.
Br J Pharmacol
106:
544-549,
1992[Abstract].
56.
Zinner, MJ,
McFadden D,
Sherlork D,
and
Jaffe BM.
Verapamil reversal of serotonin-induced jejunal secretion of water and electrolytes in awake dogs.
Gastroenterology
90:
515-519,
1986[ISI][Medline].
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Visit Other APS Journals Online |